Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 15 articles:
HTML format



Single Articles


    February 2024
  1. NAEEM AA, Abdulsamad SA, Zeng H, He G, et al
    FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells.
    Int J Oncol. 2024;64:18.
    PubMed     Abstract available


  2. ZHONG K, Luo W, Li N, Tan X, et al
    CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
    Int J Oncol. 2024;64:20.
    PubMed     Abstract available


    January 2024
  3. SUN X, Xin S, Zhang Y, Jin L, et al
    [Corrigendum] Long non?coding RNA CASC11 interacts with YBX1 to promote prostate cancer progression by suppressing the p53 pathway.
    Int J Oncol. 2024;64:5.
    PubMed     Abstract available


    November 2023
  4. FENG K, Liu C, Wang W, Kong P, et al
    Emerging proteins involved in castration?resistant prostate cancer via the AR?dependent and AR?independent pathways (Review).
    Int J Oncol. 2023;63:127.
    PubMed     Abstract available


    June 2023
  5. ZHANG Z, Wang W, Kong P, Feng K, et al
    New insights into lipid metabolism and prostate cancer (Review).
    Int J Oncol. 2023;62:74.
    PubMed     Abstract available


    March 2023
  6. SHI SJ, Han DH, Zhang JL, Li Y, et al
    VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization.
    Int J Oncol. 2023;62:34.
    PubMed     Abstract available


  7. MASUD N, Aldahish A, Iczkowski KA, Kale A, et al
    Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer.
    Int J Oncol. 2023;62:38.
    PubMed     Abstract available


    February 2023
  8. PAN D, Jia Z, Li W, Dou Z, et al
    [Corrigendum] The targeting of MTDH by miR‑145‑5p or miR‑145‑3p is associated with prognosis and regulates the growth and metastasis of prostate cancer cells.
    Int J Oncol. 2023;62:29.
    PubMed     Abstract available


    January 2023
  9. CHEN B, Liu C, Long H, Bai G, et al
    N(6)‑methyladenosine‑induced long non‑coding RNA PVT1 regulates the miR‑27b‑3p/BLM axis to promote prostate cancer progression.
    Int J Oncol. 2023;62:16.
    PubMed     Abstract available


    September 2022
  10. SUN X, Xin S, Zhang Y, Jin L, et al
    Long noncoding RNA CASC11 interacts with YBX1 to promote prostate cancer progression by suppressing the p53 pathway.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    June 2022
  11. GOULIELMAKI M, Davanos N, Kogionou P, Batsaki P, et al
    The impact of radiation therapy on the TCR Vbeta chain repertoire in patients with prostate cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    May 2022
  12. CAO J, Chan WC, Chow MSS
    Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    April 2022
  13. HE Z, Gao Y, Li T, Yu C, et al
    HepaCAMPIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    December 2021
  14. PAN XW, Gan SS, Ye JQ, Fan YH, et al
    [Corrigendum] SMC1A promotes growth and migration of prostate cancer in vitro and in vivo.
    Int J Oncol. 2021;59.
    PubMed     Abstract available


    July 2021
  15. LU S, Dong Z
    Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptormediated signaling.
    Int J Oncol. 2021;59.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.